Cardlytics CFO Departs; Interim CFO Appointed
Ticker: CDLX · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1666071
| Field | Detail |
|---|---|
| Company | Cardlytics, Inc. (CDLX) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $30,000, $10,000, $15,000, $165,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-departure, cfo, interim-appointment
Related Tickers: CDLX
TL;DR
Cardlytics CFO out April 12, interim CFO steps in.
AI Summary
Cardlytics, Inc. announced on April 9, 2024, the departure of its Chief Financial Officer, William J. Nowell, effective April 12, 2024. The company also appointed David A. DeSimone as the interim Chief Financial Officer. DeSimone previously served as the company's Chief Accounting Officer.
Why It Matters
The sudden departure of a CFO can signal internal challenges or strategic shifts, potentially impacting investor confidence and the company's financial direction.
Risk Assessment
Risk Level: medium — A CFO departure, especially without a permanent replacement named, can introduce uncertainty regarding financial strategy and leadership stability.
Key Players & Entities
- Cardlytics, Inc. (company) — The company filing the report.
- William J. Nowell (person) — Departing Chief Financial Officer.
- April 12, 2024 (date) — Effective date of CFO's departure.
- David A. DeSimone (person) — Appointed interim Chief Financial Officer.
- April 9, 2024 (date) — Date of the report.
FAQ
Who is replacing William J. Nowell as CFO?
David A. DeSimone has been appointed as the interim Chief Financial Officer.
When is William J. Nowell's departure effective?
William J. Nowell's departure is effective April 12, 2024.
What was David A. DeSimone's previous role at Cardlytics?
David A. DeSimone previously served as the company's Chief Accounting Officer.
What is the exact date of this 8-K filing?
The Form 8-K filing is dated April 9, 2024.
What specific item information is being reported in this 8-K?
This 8-K reports on the Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
Filing Stats: 982 words · 4 min read · ~3 pages · Grade level 10.9 · Accepted 2024-04-09 16:03:59
Key Financial Figures
- $30,000 — . Hornsey will be entitled to receive a $30,000 annual retainer for her service as dire
- $10,000 — ainer for her service as director and a $10,000 annual retainer for her service as a me
- $15,000 — e Compensation Committee (increasing to $15,000 upon her appointment as chair of the Co
- $165,000 — t award with a grant date fair value of $165,000 (provided that in no event will the awa
Filing Documents
- cdlx-20240409.htm (8-K) — 34KB
- cdlx_formx042023xnewboardm.htm (EX-99.1) — 5KB
- cdlx-20240409_g1.jpg (GRAPHIC) — 26KB
- 0001666071-24-000063.txt ( ) — 256KB
- cdlx-20240409.xsd (EX-101.SCH) — 3KB
- cdlx-20240409_def.xml (EX-101.DEF) — 14KB
- cdlx-20240409_lab.xml (EX-101.LAB) — 25KB
- cdlx-20240409_pre.xml (EX-101.PRE) — 15KB
- cdlx-20240409_htm.xml (XML) — 3KB
01 REGULATION FD DISCLOSURE
ITEM 7.01 REGULATION FD DISCLOSURE On April 9, 2024, the Company issued a press release announcing the appointment of Ms. Hornsey. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report. The information contained in the press release furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.
01 FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS (d) Exhibits. Exhibit Exhibit Description 99.1 P ress release dated April 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Cardlytics, Inc. Date: April 9, 2024 By: /s/ Alexis DeSieno Alexis DeSieno Chief Financial Officer (Principal Financial and Accounting Officer)